3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 2/3
1
Phase 1/2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
1
Neoplasm Metastasis
1
Drug-Related Side Effects and Adverse Reactions
1
Interventions
Cyclophosphamide
37
Gemcitabine
31
Paclitaxel
28
Cisplatin
28
Carboplatin
27
Capecitabine
27
camrelizumab
25
Nivolumab
24
apatinib
23
Oxaliplatin
21
fludarabine
20
Radiotherapy
20
toripalimab
19
Drug Therapy
18
Immunotherapy, Adoptive
17
pembrolizumab
16
Docetaxel
16
Bevacizumab
16
Dexamethasone
15
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
14
Injections
14
tislelizumab
13
Temozolomide
13
Rituximab
13
Cetuximab
13
Irinotecan
12
Fluorouracil
11
130-nm albumin-bound paclitaxel
11
anlotinib
10
Trastuzumab
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Unknown
×
Drug Combinations
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled